Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines

Prostate

Volumn 40, Issue 4, 1999, Pages 269-273

  Pflug, Beth R ^a   Reiter, Robert E ^b   Nelson, Joel B ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Androgen independence; Androgen regulation; Caveolin; Prostate; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CAVEOLIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CELL CULTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CASTRATION; CAVEOLIN 1; CAVEOLINS; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROSTATE; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; TUMOR CELLS, CULTURED;

EID: 0032806788     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990901)40:4<269::AID-PROS9>3.0.CO;2-6     Document Type: Article

References (28)

1. Engelman JA, Zhang XL, Galbiati F, Volonte D, Sotgia F, Pestell RG, Minetti C, Scherer PE, Okamoto T, Lisanti MP. Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Am J Hum Gent 1998;63:1578-1587.
2. Lisanti MP, Scherer PE, Vidugiriene J, Tang ZL, Hermanowski-Vosatka A, Tu Y-H, Cook RF, Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from endothelial-rich source: implications for human disease. J Cell Biol 1994;126: 111-126.
3. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-1880.
4. Nasu Y, Timme T, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen insensitive mouse prostate cancer cells. Nature Med 1998;4: 1062-1064.
5. Nelson JB. Alternatives to death: understanding androgen-independent prostate cancer. Nature Med 1998;4:1011-1012.
6. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999;24:580586.
7. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998;16:1391-1397.
8. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995;92:1381-1385.
9. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte O, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med 1997;3:402-408.
10. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vassella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95: 5426-5450.
11. Clark GJ, Cox AD, Graham SM, Der CJ. Biological assays for ras transformation. In: Abelson JN, Simon MI, editors. Methods in enzymology, small GTPases and their regulators, Part A. San Diego: Academic Press; 1995. p 395-412.
12. Chun M, Liyanage UK, Lisanti MP, Lodish HF. Signal transduction of a G protein-coupled receptor in caveolae: Colocalization of endothelin and its receptor with caveolin. Proc Natl Acad Sci USA 1994;91:11728-11732.
13. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998;17:6633-6648.
14. Galbiati F, Volonte D, Gil O, Zanazzi G, Salzer JL, Sargiacomo M, Scherer PE, Engelman JA, Schlegel A, Parenti M, Okamoto T, Lisanti MP. Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is upregulated in response to cell injury. Proc Natl Acad Sci USA 1998;95:10257-10262.
15. Engleman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997;272:16374-16381.
16. Kasper M, Reimann T, Hempel U, Wenzel KW, Bierhaus A, Schuh D, Dimmer V, Haroske G, Muller M. Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alteration during lung fibrogenesis. Histochem and Cell Biol 1998;109:41-48.
17. Engleman JA, Zhang XL, Galbiati F, Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1,-2,and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Letters 1998;429:330-336.
18. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-3102.
19. Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998;9:403-410.
20. Li S, Couet J, Lisanti MP. Src tyrosine kinases, G alpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996;271: 29182-29190.
21. Yamamoto M, Toy a Y, Schwencke C, Lisanti MP, Myers MG, Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 1998;273:26962-26968.
22. NTR and regulates neurotrophin signaling pathways. J Biol Chem 1999;274:257-263.
23. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997;272:30429-30438.
24. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LWK. C-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-298.
25. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Up-regulation of caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998;20:368-372.
26. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999;24:580-586.
27. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistent cancer cells. J Biol Chem 1998;273:32380-32383.
28. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, Parkinson EK, Black DM. Analysis of the caveolin-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999;18:1881-1890.